The effect of fluconazole combined with amphotericin B on highly toxic miR-15b and TGF-β1 of cronobacter in neonates

Objective: To analyze the effects of fluconazole combined with amphotericin B on the levels of miR-15b and transforming growth factor-β1 in patients with cronobacter in neonates. Methods: Using the random number table method, twenty-eight patients who were admitted to our hospital between January 2018 and January 2021 with cronobacter pneumonia were chosen and split into two groups: the control group and the observation group. For 14 days, they received either fluconazole with amphotericin B or amphotericin B alone. The pulmonary function forced expiratory volume in one second (FEV1) and forced vital (FORCED vital) of the two groups were observed and recorded Capacity (FVC), forced expiratory volume/forced vital volume in one second/orced vital Capacity, FEV1/FVC), procalcitonin (PCT), soluble receptor expressed on myeloid (Triggering receptor expressed on myeloid) Cells-1, StreM-1), Mir-15b and TGF-β1, and the clinical efficacy was evaluated. Results: After treatment, the levels of FEV1, FVC and FEV1/FVC in patients were increased, and the levels of FEV1, FVC and FEV1/FVC in observation group were higher than those in control group (P < 0.05). After treatment, the levels of PCT and sTREM-1 were decreased, while the levels of miR-15b and TGF-β1 were increased. Compared with the control group, the levels of PCT and TREM-1 were lower in the observation group, while the levels of miR-15b and TGF-β1 were higher (P < 0.05). The total effective rate of observation group (92.86%) was significantly higher than that of control group (57.14%), the difference was statistically significant (P < 0.05). Conclusion: Fluconazole plus amphotericin B has demonstrated clinical efficacy in treating patients with cronobacter pneumonia in neonates. It can effectively improve the inflammatory state of the body, miR-15b, and TGF-β1, as well as aid in improving lung function with fewer side effects and high safety.